What biomarker testing is recommended for locally advanced Ovarian Cancer

Biomarker Testing for Locally Advanced Ovarian Cancer

I'll walk you through what testing is recommended at diagnosis for ovarian cancer, based on current medical guidelines.

Initial Biomarker Testing at Diagnosis

According to NCCN Guidelines for Ovarian Cancer, when you're first diagnosed with ovarian cancer, your care team should perform specific molecular testing on your tumor tissue. Here's what's typically recommended:

Primary Molecular Tests (Most Important)

BRCA1/2 Testing - This is the priority test

• Checks for inherited mutations in genes that affect DNA repair
• Critical because it directly determines which maintenance therapies you may be eligible for after chemotherapy
• Both germline testing (inherited mutations) and somatic testing (mutations in the cancer cells only) should be done

Homologous Recombination Status (HRD)

• Assesses how well your cancer cells can repair DNA damage
• If you don't have a BRCA mutation, HRD status helps predict how much benefit you might get from PARP inhibitor maintenance therapy (drugs that target DNA repair defects)
• This includes testing for "loss of heterozygosity" (LOH)

Additional Tumor Markers (Depending on Your Situation)

CA-125

• The most commonly used tumor marker for ovarian cancer
• Helps establish a baseline before treatment
• Useful for monitoring how well treatment is working
• Can help detect recurrence during follow-up

HE4 (Human Epididymis Protein 4)

• Some oncologists test this, especially if your CA-125 isn't elevated
• May be helpful for future monitoring during treatment and surveillance
• According to NCCN, it's not routinely required but can be useful in certain cases

---

Important Clinical Context

Why This Matters for Your Treatment Plan:

According to NCCN Guidelines, BRCA1/2 and HRD status directly influence what happens after your initial chemotherapy. If you have a BRCA mutation or HRD-positive status, you become eligible for PARP inhibitor maintenance therapy — drugs specifically designed to target these DNA repair defects. This can significantly extend the time before your cancer returns.

---

Testing Logistics

Where Testing Happens:

• Testing should be performed in a CLIA-approved laboratory (Clinical Laboratory Improvement Amendments — this ensures quality standards)
• Can be done on tumor tissue from surgery or biopsy
• If tissue isn't available, circulating tumor DNA (ctDNA) testing — a blood test — can sometimes be used

Timing:

• Ideally done on the most recent tumor tissue available
• Should be completed before or early in your treatment planning

---

Questions to Ask Your Oncology Team

1. "Have my BRCA1/2 status and HRD status been tested? If not, when will this happen?"
2. "What do my specific test results mean for my treatment options?"
3. "Am I eligible for PARP inhibitor maintenance therapy based on my molecular results?"
4. "Will you be monitoring CA-125 during and after my treatment?"
5. "If my initial testing was done on a biopsy, will you do additional testing on my surgical specimen?"

---

Key Takeaway

For locally advanced ovarian cancer, BRCA1/2 and HRD testing are the priority because they directly guide your maintenance therapy options after chemotherapy. CA-125 and HE4 are useful for monitoring your response to treatment and watching for recurrence, but the molecular tests are what shape your overall treatment strategy.

According to the NCCN Guidelines, this testing should happen as part of your standard workup — it's not optional, it's foundational to personalized treatment planning.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.